• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends



Pharmaceutical Executive

Pharmaceutical ExecutivePharmaceutical Executive-05-01-2005
Volume 0
Issue 0

Cover Story

Cover Story

Pharma's Top 50: Our 6th Annual Report

Nicole Gray

Contributing Writer

This year's list of the top 50-ranked pharma companies includes movers, mainstays, mergers, and more.



Ad Stars

Joanna Breitstein

Senior Editor

A new Pharm Exec feature: Meet the teams behind some of the top pharma ad campaigns of 2004.


Eisai's New Leadership

Joanna Breitstein

Senior Writer

US president and COO Lonnel Coats, and chairman and CEO Hajime Shimizu, talk about their first year at the helm of Eisai.

Clinical Trials

Site Selection

Richard Gliklich, MD


In the fast-growing world of post-approval studies, competition for research sites is heating up. Here's how to play the game.


Elephant or Specialist?

Eric Felker

Apollo Consulting Group

Medicare wants to create new market forces to drive down costs. How should you respond? First you need to know what you are.

Call Centers

Beyond the Call

Stan Zehner and Beth Ann Pelegan

RWD Technologies

Sure, an integrated call center system can make phone operators' jobs easier. But there's a much better reason to use one.

Cutting Edge

It's All About Immunity

L.J. Sellers

Contributing Writer

After 9/11, San Diego-based Hollis-Eden discovered a new mission: developing an FDA-approved treatment for acute radiation sickness.

Special Report: Spend Trends

Changing Lanes

Diane West

Contributing Writer

Analysts predict that the booming DTC advertising market is about to shift from branded campaigns to disease-awareness efforts.

Leading Indicators


Giuliani's research group pokes holes in drug importation plans " WHO calls for international treaty to combat counterfeiting of drugs " FDA bans inhalers that use chlorofluorocarbon propellants " Pfizer gets warned about Zyrtec ads " Part B: the new Part D


Americans fail compliance test " Potential problems with Part B price controls " Mental health meds are in high demand

Thought Leaders

Lisa Drakeman, Genmab's CEO, on the art of biotech dealmaking.

Washington Report

Some think recent withdrawal actions signal a more risk-averse stance at FDA; cynics say it's just another swing of the regulatory pendulum.

Jill Wechsler

Global Report

Government officials in the UK are calling for tougher regulations of pharma.

Sarah Houlton


Two perspectives on achieving work/life balance.

Sander Flaum Flaum Partners

Jonathon Flaum WriteMind Communications

Legal Forum

Patent rulings have limited the use of costly research tools. Researchers are coming up with answers.

Margaret Buck

Cozen O'Connor

Strategy & Tactics

Direct to Consumer

Increasingly, patients are looking for an education in healthcare. For pharma, that's a great opportunity.

Kathy Kastner

The Health Television System

Marketing to Professionals

Why don't we know more about the doctors we spend so much money marketing to?

Jason Hogg


Alternative Media

To reach $1 billion in sales,


took a unique marketing approach.

Benjamin White


Medical Education

The Baby Boomers are going gray. If the healthcare system doesn't adjust—and soon—it's going to be overwhelmed.

Marsha Meyer


Public Relations

Round-the-clock access to medical news has made it hard for doctors to stay one step ahead of patients.

Ame Wadler


Tool Kit

How to spice up science-heavy presentations.

Karen Friedman

Karen Friedman Enterprises


From the Editor

A new TV show has created the world's most loathsome pharma exec. Now, here's the good news . . .

Patrick Clinton


Opinion Column

Marketers and FDA must work to transform frightened Americans into engaged Americans.

Peter Pitts

Manning, Selvage & Lee

Back Page

The Medicare exclusion statute is a death sentence for pharma companies.

Robert Ullmann

Nutter McClennen & Fish


People Update

Calendar of Events

Advertisers Index

Recent Videos
Related Content